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ABSTRACT 
Background: High iron measured using dietary and serum biomarkers have been associated 
with type 2 diabetes; however it is uncertain whether a similar association exists for 
gestational diabetes mellitus (GDM).  
Objectives: To conduct a cohort study examining first trimester body iron stores and 
subsequent risk of GDM and to include these findings in a systematic review of all studies 
examining the association between maternal iron status, iron intake (dietary and 
supplemental) and the risk of GDM.   
Methods:  Serum samples for women with first trimester screening were linked to birth and 
hospital records for data on maternal characteristics and GDM diagnosis. Blood was analysed 
for ferritin, soluble transferrin receptor (sTfR) and C-reactive protein (CRP).  Associations 
between iron biomarkers and GDM were assessed using multivariate logistic regression. A 
systematic review and meta-analysis, registered with PROSPERO (CRD42014013663) 
included all studies published in English from Jan 1995 to March 2014 that examined the 
association between iron and GDM and included an appropriate comparison group.  
Results: Of 3, 776 women, 3.4% subsequently developed GDM. Adjusted analyses found 
increased odds of GDM for ferritin (OR 1.41; 95% CI: 1.11, 1.78) but not for sTfR (OR 1.00, 
95% CI: 0.97, 1.03) levels. Two trials of iron supplementation in early pregnancy found no 
association with GDM.  Increased risk of GDM was associated with higher levels of maternal 
ferritin and serum iron and dietary heme iron intakes. 
Conclusions: Increased risk of GDM among women with high serum ferritin and iron levels 
and dietary heme iron intakes warrants further investigation.  
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INTRODUCTION 
Iron is a transitional metal that is essential for several physiological functions in the body (a 
micronutrient), but excessive levels can be pathological.1 The role of iron in diabetic 
pathogenesis was first identified by increased rates of diabetes (25-60%) in individuals with 
hereditary haemochromatosis, an inherited iron overload syndrome.2  Even in the absence of 
significant iron overload, studies in general populations have found that high dietary intakes 
of red meat and heme iron (animal sources) are associated with risk of type 2 diabetes3-5 and 
that moderately elevated ferritin levels (biomarker of iron stores) are associated with 
increased insulin secretion, decreased insulin sensitivity and type 2 diabetes.3,4,6    
 
The association between excess iron and type 2 diabetes mellitus has lead to concern that 
these may also affect gestational diabetes mellitus (GDM).  In pregnant women, there has 
been concern that high intakes of supplemental iron by iron-replete pregnant women may 
lead to increased amounts of unabsorbed iron in the intestine and result in local oxidative 
stress,7 damage of pancreatic beta cells, increased insulin resistance and subsequently the 
development of diabetes.8     
 
Results from previous studies examining the risk of GDM in relation to elevated iron, 
measured as iron intakes (dietary and supplemental)9-11 or serum ferritin levels have been 
inconsistent.12-17  Differences in study findings may be due to differences in study 
populations, timing of data collection for iron exposure, thresholds for elevated iron levels, 
and adjustment for confounders including inflammation.  
 
While there have been a number of systematic reviews examining the association between 
iron intake, body iron stores and the risk of type 2 diabetes in general populations,3,4,6  to our 
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knowledge, a systematic review has not yet been performed that examines maternal serum 
iron biomarkers, iron intake and risk of GDM.  Therefore, the aims of this study were 
twofold: i) to conduct a cohort study examining first trimester body iron stores and 
subsequent risk of GDM and; ii) to systematically review studies of all designs examining the 
association between maternal iron status, iron intake (dietary and supplemental), and the risk 
of GDM.   
 
METHODS  
In-house study 
The study population included pregnant women who attended first trimester Down syndrome 
screening between January and October 2007 and had their sera analyzed and subsequently 
archived by Pathology North laboratory, a state-wide public screening service in New South 
Wales, Australia.   
 
For this study, sera were thawed and analyzed to assess serum ferritin (µg/L), soluble 
transferrrin receptor (sTfR; nmol/L) and C-reactive protein (CRP; mg/L) using commercial 
assays. Serum ferritin was measured using a solid phase direct sandwich ELISA method 
(Calbiotech, Inc, CA, USA) with an interassay CV of 6.2%. sTfR was measured using an 
enzyme-linked immunosorbent assay (Quantikine IVD, Human sTfR Immunoassay, R & D 
Systems, Minneapolis, MN, USA) with an interassay CV of 6.4%.  CRP was measured using 
the quantitative sandwich enzyme immunoassay technique (QUANTIKINE™, Minneapolis, 
USA) with an interassay CV of 13.3%.   
 
Maternal information and first trimester screening results derived from the laboratory 
database were combined via record linkage with women’s corresponding health records from 
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routinely collected birth and hospital databases to obtain information on their pregnancy and 
infant outcomes. ‘Birth data’ were sourced from the NSW Perinatal Data Collection (PDC) 
and ‘hospitalisation data’ from the NSW Admitted Patients Data Collection (APDC). The 
PDC is a statutory population-based collection of all births in NSW of at least 400 grams 
birth weight or at least 20 weeks of gestation, and includes information on maternal and 
infant characteristics, pregnancy, labor, delivery and infant characteristics at birth. The 
APDC is a census of all admissions in NSW public and private hospitals. Up to 50 diagnosis 
and procedures for each separation are coded according to the 10th revision of the 
International Classification of Diseases, Australian Modification (ICD-10-AM).18  Only 
variables known to be reliably reported in birth and/or hospital data were included in the 
analysis. For these variables, reporting in both datasets had high specificity (>99%) 
indicating few false positive reports and validation studies of the PDC and the APDC showed 
excellent level of agreement with the hospital medical record and low rates of missing 
data.19,20 The NSW Centre for Health Record Linkage (CHeReL) performed probabilistic 
record linkage between the three datasets.21 The CHeReL assesses the linkage quality for 
each study and, for this study, reported <5/1000 missed links and <2/1000 false positive 
links. Only de-identified data were provided to the researchers. The study was approved by 
the NSW Population and Health Services Research Ethics Committee (HREC/09/CIPHS/52). 
 
The primary outcome was gestational diabetes mellitus (GDM). Information on GDM and 
pre-existing diabetes were identified from hospital records based on diagnosis by the 
attending clinician.20,22,23  Validation studies of the hospital data indicate 69%-96% 
ascertainment of GDM with few false positives, and 100% ascertainment of pre-existing 
diabetes with no false positives.20,22  These sensitivity and specificity values are in keeping 
6 
 
with those reported by other international validation studies of birth and hospital records for 
identification of GDM and pre-existing diabetes.23   
 
The primary exposure of interest was serum ferritin. As there is no established cut-off for 
elevated ferritin levels, we assessed serum ferritin concentrations as a continuous measure 
and using three cut-offs based on the highest tertile (>66th percentile), highest quartile (>75th 
percentile) and highest quintile (>80th percentile).  These cut-offs were selected to allow us to 
compare our results with those used in previous GDM studies.15,16   
 
Explanatory variables included in the analyses were: maternal age, country of birth, parity, 
maternal weight, smoking during pregnancy, hypertensive disorders of pregnancy and CRP 
concentrations.  Countries of birth classified as high-risk for GDM included Oceania, 
Southern and Eastern Europe, Middle East and North Africa, South-East Asia, Southern and 
Central Asia.24  Maternal postcode of residence was used to derive an indicator of 
socioeconomic status (SES). An Index of Relative Disadvantage, produced by the Australian 
Bureau of Statistics, was assigned to each postcode and quintiles produced with women in the 
lowest 20th percentile classified as most disadvantaged.  Hypertensive disorders in pregnancy 
were defined as women with the onset of hypertension from 20 weeks gestation including 
gestational hypertension, preeclampsia and eclampsia.25   
 
Descriptive statistics were used to assess maternal and pregnancy characteristics as well as 
iron and inflammatory biomarker concentrations by GDM status.  The distribution of 
biomarkers was assessed and those without normal distribution (ferritin and CRP) were log-
transformed.  Multivariate logistic regression analysis was performed to determine the 
association between serum ferritin and sTfR concentrations and risk of GDM adjusting for 
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explanatory variables and CRP levels.  Results are presented using odds ratio (OR) and 95% 
confidence intervals (CI).  Statistical analyses were performed using SAS for Windows 
version 9.3 (SAS Institute Inc, Carey, North Carolina).    
 
Systematic review and meta-analyses 
The systematic review and meta-analysis was conducted and reported using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA),26 and where 
applicable, the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
guidelines.27 This systematic review has been registered with the international prospective 
register of systematic reviews (PROSPERO) as number CRD42014013663. 
 
We searched PubMed, MEDLINE and EMBASE and CINAHL from 01 January 1995 to 01 
March 2014.    Electronic searches combined keyword and MeSH search terms related to 
diabetes, gestational, hyperglycemia, glucose, insulin, iron, and iron-binding proteins.   We 
also reviewed the reference lists of identiﬁed articles. The search was restricted to studies of 
humans, and those published in English.  Full search strategies are provided in 
Supplementary Table 1. 
 
To be included, studies had to restrict their study population to pregnant women, defined 
GDM as the primary outcome, include an appropriate control or comparison group, and 
examine iron as the exposure of interest.  Excess or additional iron could be defined as an 
intervention (i.e. iron supplement) or measured using at least one iron biomarker or dietary 
intake data.  Eligible study designs included trials, cohort, case-control and cross-sectional 
studies.  Two investigators (AK, PN) independently evaluated the eligibility of all retrieved 
studies.  Where there was disagreement at this stage, the article remained included until the 
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full text was reviewed. Each full text article was assessed independently by two investigators 
using the aforementioned inclusion criteria and any disagreement regarding eligibility of an 
article was discussed to reach agreement by consensus. Where information pertinent to the 
inclusion criteria was not reported in the article, efforts were made to contact the listed 
corresponding author. Where no reply was received, the article was excluded.  
 
Data were extracted by two investigators (AK, AA) on the article (author, publication year, 
journal name), study characteristics (study design, geographical location, population source, 
duration of follow-up), participant characteristics (sample size, age, number of GDM events, 
numbers of controls), assessment of iron (dietary intakes, plasma/serum, dose/frequency of 
iron supplement), ascertainment of GDM, measurement and adjustment for inflammatory 
markers such as C-reactive protein (CRP), statistical methods used for the analysis, 
comparison group, risk estimates and 95% CIs, and any covariates that were matched on, or 
adjusted for, in the multivariate analyses.  
 
Quality assessment was conducted by two independent reviewers (AK, AA) using 
standardised measures. Randomised studies were evaluated using the Cochrane 
Collaboration’s tool for assessing risk of bias.28 This tool provides a model to evaluate the 
risk of bias across a number of domains: how a study selects participants, measures 
performance, blinds participants and investigators, explores attrition, and reports findings.  
Risk of bias for each domain was allocated a ranking of “low” (score=2), “unclear” 
(score=1), or “high” (score=0).  Study quality for cohort and case-control studies was 
assessed using the nine-star Newcastle–Ottawa Scale for observational studies.29   
Independent scores from each assessor were averaged and expressed as a percentage. 
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Study findings were summarized descriptively by study design and where possible sub-group 
comparisons presented in tabular form for studies with comparable exposure measurements 
and reporting of findings.  Descriptive and outcome data from the in-house study were 
included for comparison with other iron biomarker studies.  Iron biomarker concentrations 
were converted to the same units (mean values) and mean differences were computed 
between cases and controls for each study so that data could be summarized using forest 
plots.  Forest plots were performed for all studies with available data and in sub-groups based 
on common factors.   The extent of heterogeneity was measured using I2 statistic, a measure 
of the proportion of total variability explained by heterogeneity and expressed as a percentage 
of heterogenity, with 0–40% indicating might not be important, 30-60% indicating may 
represent moderate heterogenity, 50-90% indicating may represent substantial heterogenity 
and 75-100% indicating considerable heterogenity.30  Data were analysed using RevMan, 
version 5.3. 
 
 
RESULTS 
In-house study 
A total of 3, 776 women were included in the analysis after excluding 124 women with pre-
existing diabetes, a twin pregnancy, medical abortion, infant with a major congenital anomaly 
or an undetectable ferritin measurement. There were 129 women (3.4%) diagnosed with 
GDM and 3, 647 women who were not diagnosed with GDM.  Women with GDM were more 
likely to be older, from a country identified as high risk for GDM, heavier and diagnosed 
with hypertensive disorders of pregnancy (Table 1).  They also had significantly higher 
median serum ferritin concentrations (32.8 vs. 24.8 µg/L, P=0.001) and were less likely to 
have iron deficiency (<12 µg/L) (9.3% vs. 19.9%, P=0.003).  Women with GDM were also 
more likely to have CRP levels >90th percentile (2.8 mg/L) indicative of inflammation 
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(14.8% vs. 9.5%, P=0.05).  There were no differences between GDM and non-GDM women 
in median TfR concentrations (15.7 vs. 15.1 nmol/L, P=0.11).  
 
Results for univariate and multivariate logistic regression analyses examining the odds of 
GDM for maternal serum ferritin and sTfR concentrations are presented in Table 2.  
Multivariate analyses found increased risk of GDM when ferritin was examined as a 
continuous variable (adjusted odds ratio (AOR): 1.41; 95% CI: 1.11, 1.78) and when elevated 
ferritin was defined using the highest tertile (≥35 µg/L) (AOR 1.60, 95% CI: 1.03-2.49).  
Increased odds of GDM but did not reach statistical significance for ferritin levels defined as 
the highest quartile (≥43 µg/L) (AOR: 1.39; 95% CI: 0.93, 2.06) or the highest quintile (≥48 
µg/L) (AOR: 1.43, 95% CI: 0.95, 2.16).  There was no association between sTfR 
concentrations and GDM (AOR 1.00, 95% CI: 0.97, 1.03).  
 
Systematic review and meta-analyses 
Of 714 citations identified in the search strategy, 18 articles met the inclusion criteria (Figure 
1).   There were two randomized controlled trials, three cohort studies and 13 case-control 
studies.   Tables 3a-c presents study characteristics and quality assessment scores categorised 
by different measurements of iron exposure.  Both trials assessed iron supplement use in 
early pregnancy and found no association with risk of GDM (Table 3a).10,31   The Chan et al. 
trial was well-designed and scored high (92%) in the quality assessment.10  The other trial 
scored poorly on the quality assessment (58%) and did not report on method of 
randomization or blinding, suffered from considerable loss to follow-up and measured the 
primary outcome of GDM using a questionnaire.32   
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There were three cohort studies which examined dietary iron intake during pregnancy and 
risk of GDM (Table 3b).9,11,33 All three studies had moderate to high quality assessment 
scores (72-95%).  Each of these studies used a different threshold for elevated dietary iron 
intake. The Finnish study by Helin et al. found no significance difference in total iron intake 
using >80 percentile cut-point (AOR: 1.66, 95% CI: 0.84 - 3.30).11 The other two studies 
found a significant association for dietary heme iron intake but not for non-heme iron.9,33  
Bowers et al., using data from the Nurses’ Health Study in the USA, found the adjusted 
relative risks (RR) (95% CIs) of GDM across increasing quintiles of heme iron were 1.0 
(lowest reference), 1.11 (0.87, 1.43), 1.31 (1.03, 1.68), 1.51 (1.17, 1.93), and 1.58 (1.21, 
2.08), respectively (P for linear trend <0.0001). For every 0.5-mg per day of increase in iron 
intake, the adjusted RR of GDM increased by 1.22 (95% CI: 1.10, 1.36).9  Qiu, 2011, using 
data from the Omega Study also conducted in the USA, found adjusted RR across increasing 
quartiles of heme iron were 1.0 (reference), 1.27 (0.77, 2.09), 1.41 (95% CI: 0.81, 2.44) and 
2.15 (95% CI: 1.09, 4.27), respectively (P for linear trends 0.04).33  The multivariate adjusted 
RR for GDM associated with 1-mg per day increase in heme iron intake was 1.51 (95% CI: 
0.99, 2.36).   
 
There were 13 case-control studies which examined the association between high serum iron 
levels and GDM (Table 3c).  The quality assessment scores varied; with only three studies 
scoring higher than 75%.16,34,35   Only one case-control study  measured serum ferritin in 
early pregnancy,15 and two studies15,16 assessed an inflammatory biomarker, which in both 
studies was CRP.  Overall, limitations of these studies included non-representative study 
populations from a single clinic or hospital setting; small sample sizes ranging from 6 to 64 
GDM cases, inconsistent thresholds for elevated ferritin levels and lack of data on other iron 
and inflammatory biomarkers. 
12 
 
 
Most iron biomarker studies used descriptive statistics to compare mean or median biomarker 
concentrations in GDM and non-GDM pregnancies; with inconsistent findings across studies 
(Table 4).12-17   Only 3 of the 14 studies adjusted for confounders.14-16 Behboudi-Gandevani 
et al. found serum iron levels examined on a continuous scale were associated with GDM 
(AOR 1.01, 95% CI 1.00–1.01).14  Chen et al. found  women with the highest tertile of 
ferritin levels (≥92.1 μgl/L) were not significantly at increased risk of GDM (adjusted odds 
ratio (AOR 1.88, 95% CI 0.81–4.36),15 and Sharifi et al. found women in the highest quartile 
of serum ferritin (>84.7 μgl/L) had a greater than two-fold increased risk of GDM (AOR 
2.30, 95% CI 1.06–5.10).16   
 
Including serum ferritin data from the in-house study, results from pooled analyses reveal that 
women with GDM had higher concentrations of serum ferritin (mean differencepooled 23.6 
pmol/L, 95% CI 21.1, 26.1, I2: 96%, test for overall effect P<0.00001) (Figure 2a).  To 
examine heterogeneity, pooled analyses of serum ferritin concentrations were performed 
excluding 3 studies that had a quality assessment score <70%31 or that had a high proportion 
of overweight/obese participants.15,16  Exclusion of these studies decreased heterogeneity 
from 96% to 49% but did not change the direction of the pooled analysis (mean 
differencepooled 13.5 pmol/L, 95% CI 8.8, 18.2, I2: 49%, test for overall effect P<0.00001) 
(Figure 2b). 
 
Results from pooled analyses of serum iron concentrations reveal that women with GDM had 
higher concentrations of serum iron concentrations (mean differencepooled 208.2 mcg/L, 95% 
CI 152.4, 264.0, I2: 89%) (Figure 3).  For serum iron concentrations, attempts to decrease 
heterogeneity between pooled analyses by excluding studies with low quality assessment 
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scores or by conducting separate pooled analyses by timing of blood sampling (<20 vs. ≥20 
weeks gestation) relatively little change in the high I2 measure.  When studies with quality 
scores ≤60% were excluded, the mean difference for pooled analyses for serum iron 
concentrations was 224.2 mcg/L (95% CI 165.8, 282.6, I2: 90%).  The mean difference in 
pooled analyses was 159.9 mcg/L (95% CI 60.3, 259.5, I2: 95%) for studies that collected 
blood samples before 20 weeks gestation and 257.9 mcg/L (95% CI 185.8, 330.1, I2: 90%) 
for studies that collected blood samples ≥20 weeks gestation.   
 
Of the case-control studies that assessed iron biomarkers other than serum ferritin and serum 
iron, 3 studies found no differences between GDM and non-GDM women in the 
concentrations of transferrin,31,35,36  transferrin saturation,36  or total iron-binding capacity 
(TIBC),35 and 3 studies found unadjusted associations between iron biomarkers (i.e. 
transferrin, transferrin saturation levels or TIBC) and GDM indicative of excess iron (Table 
3c).12,37,38  The study by Derbent et al. found that ferritin, serum iron and hepcidin levels 
measured at 24- 28 weeks of gestation were significantly higher among GDM women.34  The 
study also found that body mass index was higher in women with GDM women and was 
closely correlated with hepcidin levels; however, CRP and white blood cells (WBC) were not 
correlated to hepicidin levels.  Hepcidin was not correlated to ferritin or serum iron and was 
positively correlated to parameters of glucose metabolism (fasting blood glucose, fasting 
insulin level and glucose value response to glucose challenge test). 
 
DISCUSSION 
A better understanding of whether elevated iron increases risk of GDM is needed to identify 
high risk pregnancies that could benefit from early intervention.  This study reports on the 
association between maternal iron status, iron intake (dietary and supplemental) and the risk 
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of GDM.  Results from our in-house study indicate that elevated ferritin concentrations are 
associated with increased risk of developing GDM.  We did not find an association between 
sTfR concentrations and GDM.  Serum levels of this soluble form of TfR are directly 
proportional to the tissue TfR concentration and have been proposed as a novel marker of 
iron status that is not affected by the presence of inflammation.39  However, there is contrary 
evidence which shows that sTfR concentrations may in fact be impacted by inflammation.40  
Studies have reported lower sTfR concentrations in patients with inflammation associated 
with cancer,41 malaria,42 and HIV.43   To strengthen the results from our in-house study, we 
performed a comprehensive systematic review of the literature and incorporated results from 
our in-house study with other biomarker studies examining the association between iron and 
GDM.   
 
Results from our meta-analysis of iron biomarker studies found that higher ferritin and serum 
iron concentrations were associated with GDM.   The ferritin results are consistent with those 
from our in-house study.  The higher serum iron concentrations among women with GDM 
suggest that excess iron is associated with GDM.  Serum iron levels increase during iron 
overload and decrease during infection and inflammation because iron is trapped inside 
macrophages.44  Pooled analyses found a large amount of heterogeneity that was not 
explained after sub-group analyses were performed by study quality or timing of blood 
sampling.  One possible explanation for the heterogeneity is the diurnal variation; serum iron 
concentrations vary considerably among individuals within a single day.  While pooled 
analyses showed high heterogeneity, the pooled result was consistent and in the same 
direction across sub-group analyses.   
 
Only one study examined hepcidin, the key regulator of iron homeostasis and found that 
GDM women had significantly higher hepcidin levels.34  These findings suggest hepcidin 
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synthesis was increased as a response to increased iron rather than inflammation.40  Derbent 
et al. also found that inflammatory biomarkers, CRP and white blood cells, were not 
correlated to hepicidin levels and that hepcidin was positively correlated to parameters of 
glucose metabolism (fasting blood glucose, fasting insulin level and glucose value response 
to glucose challenge test).  This was the only study to examine maternal serum hepcidin 
values in women with GDM, therefore additional studies in other study populations are 
needed to replicate these findings.  Furthermore, the study shared many of the limitations of 
other biomarkers studies, including: non-representative study populations; restricted to single 
clinic or hospital settings; small sample sizes, not adjusting for confounders and measuring 
iron biomarkers at the time of GDM diagnosis. 
 
To further our examination of the association between iron and GDM, we also included all 
study designs in our systematic review and identified two iron supplementation trials and 
three dietary iron studies.  The two trials of iron supplementation in early pregnancy found no 
association with GDM.  Possible explanations for their null findings include short exposure 
times to iron supplements, exposure to low doses of supplemental iron, and lack of data on 
inflammation or dietary iron intakes.  The results from two high quality dietary iron intake 
studies support an increased risk of GDM among pregnant women consuming high levels 
dietary heme but not non-heme iron intake.  It has been proposed that under certain 
conditions, such as inflammation, ingestion of excess iron in certain forms (i.e. processed 
meats) may be hazardous.3,5  Dietary advanced glycation endproducts (AGEs) which are 
present in large amounts of processed red meats and in high-fat animal products have been 
associated with development of diabetes 5 and increased inflammatory plasma cytokines in 
diabetic subjects. 45  The link between AGEs and diabetes may explain why these and other 
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general population studies3-5 show high dietary intakes of red meat and heme iron (animal 
sources) are associated with risk of diabetes but not with total dietary iron or non-heme iron.  
 
Strengths of this study include an in-house study and a comprehensive systematic review on 
the broader research question.  Strengths of our in-house study include a large sample size, 
measurement of biomarkers in early pregnancy and prior to GDM, measurement of iron 
biomarker in addition to ferritin as well as an inflammatory biomarker and adjustment for a 
range of important confounders.  Limitations include lack of data on maternal anemia, iron 
supplement use, maternal diet, and insulin and glucose concentrations.   Strengths of the 
systematic review include an extensive and systematic literature search, use of explicit 
inclusion criteria, a standardised approach for extracting data and assessment of study quality 
by at least two of the authors.  Limitations include restricting our search strategy to published 
studies and those in the English language. 
 
In summary, a review of the literature to date indicates that increased risk of GDM does not 
result from short exposures to iron supplements during pregnancy but is associated with 
higher intakes of dietary heme iron during the preconceptional and early pregnancy period.  
Evidence from biomarker studies suggests that elevated iron biomarkers in GDM women 
reflect a response to excess iron rather than inflammation.  Further studies are warranted that 
better characterise iron’s role in the pathophysiological pathways that lead to GDM, that 
measure and compare multiple iron biomarkers in combination with dietary and supplemental 
sources of iron, and that identify high-risk populations for intervention studies. 
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Table 1 
Maternal and pregnancy characteristics and biochemical indices among women with and 
without gestational diabetes mellitus (GDM). 
 
 Gestational diabetes mellitus 
(GDM) 
 
 
 
 
P-value* 
 Yes 
N=129 
No 
N=3, 647 
 N (%) N (%) 
Maternal characteristics    
Maternal age, years  
 <25 
 25-34 
 ≥35 
 
 4 (3.1) 
70 (54.7) 
54 (42.2) 
 
260 (7.8) 
2094 (62.7) 
988 (29.6) 
 
0.004 
Country of birth identified as high risk for GDM¥  32 (25.0) 574 (16.1) 0.007 
Maternal weight quintiles (kg) 
 <55 
 55-60 
 61-67 
 68-76 
 ≥77 
 
23 (18.9) 
24 (19.7) 
21 (17.2) 
18 (14.8) 
36 (29.5) 
 
521 (16.8) 
652 (21.0) 
669 (21.6) 
649 (20.9) 
609 (19.7) 
 
0.05 
Smoking during pregnancy 8 (6.2) 192 (5.7) 0.70 
Socioeconomic disadvantage quintiles 
 1 (most disadvantage) 
 2 
 3 
 4 
 5 (least disadvantage) 
 
36 (27.9) 
16 (12.4) 
24 (18.6) 
21 (16.3) 
32 (24.8) 
 
685 (19.4) 
591 (16.7) 
708 (20.0) 
761 (21.5) 
788 (22.3) 
 
0.09 
Pregnancy characteristics    
Nulliparous 63 (48.8) 1747 (51.8) 0.51 
Gestational age at time of serum sampling, weeks 
 9-10 
 11 
 12-14 
 
8 (8.4) 
44 (46.3) 
43 (45.3) 
 
322 (14.6) 
785 (35.6) 
1096 (49.8) 
 
0.06 
Hypertensive disorders of pregnancy 14 (10.9) 187 (5.1) 0.009 
Biochemical indices    
Serum ferritin (µg/L), median (25th, 75th centile) 32.8 (17.3, 55.3) 24.8 (14.1, 42.2) 0.001 
Iron deficient (serum ferritin <12  µg/L) 12 (9.3) 725 (19.9) 0.003 
Transferrin receptor (TfR; nmol/L), median (25th, 75th centile)  15.7 (12.9, 19.3) 15.1 (12.2, 18.6) 0.11 
C-reactive protein (CRP; mg/L) >90th centile   19 (14.8) 338 (9.5) 0.05 
* Chi-square test and Fisher’s exact test for small cell sizes.  
¥ Countries classified as high risk included Oceania, Southern and Eastern Europe, Middle East and 
North Africa, South-East Asia, Southern and Central Asia.9   
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Table 2 
Univariate and multivariate logistic regression analysis from the in-house study examining first trimester 
maternal iron biomarkers and subsequent risk of developing gestational diabetes mellitus (GDM). 
 
 
Maternal iron biomarker 
GDM Non-
GDM 
Unadjusted odds ratio 
(OR) and 95% CI 
intervals 
Adjusted odds ratio 
(OR) and 95% CI 
intervalsa 
 
Ferritin, µg/L 
 
129 
 
3, 647 
 
1.60 (1.28, 1.99)  
 
1.41 (1.11, 1.78) 
Ferritin tertiles 
 tertile 1 (<17 µg/L) 
 tertile 2 (17-34 µg/L) 
 tertile 3 (≥35 µg/L) 
 
31 
38 
60 
 
1, 172 
1, 279 
1, 196 
 
0.89 (0.55, 1.44) 
Reference 
1.69 (1.12, 2.55) 
 
1.10 (0.67, 1.81) 
Reference 
1.60 (1.03, 2.49) 
Ferritin quartile  
 >75th percentile (≥43 µg/L) 
 
45 
 
886 
 
1.67 (1.15, 2.42) 
 
1.39 (0.93, 2.06) 
Ferritin quintile 
 >80th percentile (≥48 µg/L) 
 
39 
 
712 
 
1.79 (1.22, 2.62) 
 
1.43 (0.95, 2.16) 
 
Transferrin receptor (nmol/L) 
 
129 
 
3, 647 
 
1.02 (0.99, 1.05) 
 
1.00 (0.97, 1.03) 
a Adjusted for age, country of birth, parity, maternal weight, smoking during pregnancy, hypertensive 
disorders in pregnancy and C-reactive protein concentrations.   
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Table 3a 
Characteristics of studies identified in the systematic review examining association between iron supplement use in pregnancy and gestational 
diabetes mellitus (GDM). 
 
Study, 
country, 
quality score 
Study design Study population Intervention group  Control group Definition of 
gestational 
diabetes mellitus 
General finding 
Chan, 200910 
Hong Kong; 
92% 
Randomised 
placebo 
controlled trial 
1164 women with 
singleton pregnancies ≤16 
weeks gestation without 
anemia, 
hemoglobinopathies or 
pre-existing diabetes. 
565 women 
randomized to receive 
300 mg ferrous 
sulphate tablet daily 
(60 mg of elemental 
iron).  
599 women 
randomized to receive 
placebo tablet daily 
containing starch and 
lactose. 
Glucose testing. 
75-g OGTT at 28–
30 weeks gestation 
and OGTT at 36 
weeks (ADA 
criteria). 
No difference in GDM in study 
(n=56, 11%) vs. control (n=60, 
11.3%) groups (p=0.86). 
Ouladsaheb
madarek, 
201132 
Iran; 58% 
Double-blind-
randomized 
clinical trial 
960 women with singleton 
pregnancies in first 
trimester without anemia 
and have not taken iron 
supplement in last month. 
480 women 
randomized to receive 
daily 30 mg of 
elemental iron and 
multivitamin (contents 
not reported). 
480 women 
randomized to receive 
placebo and one 
multivitamin tablet 
daily. 
Recorded on a 
questionnaire. 
No difference in GDM in study 
(n=2, 0.5%) vs. control (n=3, 
0.8%) groups (p=0.67). 
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Table 3b 
Characteristics of studies identified in the systematic review examining dietary iron intakes in pregnant women and gestational diabetes mellitus 
(GDM). 
 
Study, 
country, 
quality score 
Study design Study population Measurement of 
dietary iron intake 
Categories for 
comparing dietary 
iron intake  
Definition of 
gestational 
diabetes mellitus 
General finding 
Bowers, 
20119 
USA; 72% 
Prospective 
cohort 
(Nurses’ 
Health Study) 
13,475/ 116,671 women 
with singleton pregnancy 
Total iron, heme, non-
heme and supplemental 
iron.  
Women in lowest 
quintile vs. women 
with intakes in 2nd, 3rd, 
4th and 5th quintiles. 
Self-reported in 
biennial 
questionnaire. 
Difference in GDM for dietary 
heme iron intake but not for non-
heme iron intake.  
 
Helin, 201211 
Finland; 95% 
Prospective 
cohort (based 
on a  cluster-
RCT where 
intervention 
and usual care 
groups were 
combined) 
399/2271 pregnant women Total daily iron intake 
during pregnancy, and 
hemoglobin in early 
pregnancy. 
Women in lowest 80th 
percentile vs. women 
in highest 20th 
percentile. 
Glucose testing. 
75g OGTT at 26-
28 weeks (ADA 
criteria). 
No significance difference in total 
iron intake. 
 
Qiu, 201133 
USA; 83% 
Prospective 
cohort (Omega 
Study) 
3158/4000 pregnant 
women 
Pre-conceptional and 
early pregnancy heme 
and nonheme iron 
intake. 
Women in lowest 
quartile vs. women in 
2nd, 3rd, and 4th 
quartiles. 
Glucose testing. 
50g 1h OGCT at 
24-28 weeks; those 
who failed had 
100g 3h OGTT 
~1-2 weeks later 
(ADA criteria). 
Difference in GDM for dietary 
heme iron intake but not for non-
heme iron intake.  
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Table 3c 
Characteristics of studies identified in the systematic review examining serum iron biomarkers in pregnant women and gestational diabetes 
mellitus (GDM). 
 
Study, 
country, 
quality score 
Study design Study population Serum iron 
biomarkers  
Selection and 
matching of controls  
Definition of 
gestational 
diabetes mellitus 
General finding 
Afkhami-
Ardekani, 
200912 
Iran; 73% 
Case-control 34 GDM cases  
34 non-GDM controls 
 
Ferritin, serum iron,  
transferrin saturation, 
total iron binding 
capacity. 
Matched by age, 
parity, 
and BMI. 
Glucose testing. 
100-g oral glucose 
load (ADA 
criteria). 
Unadjusted serum ferritin, serum 
iron, and transferrin saturation 
levels were significantly higher 
and TIBC was significantly lower 
in the GDM group. 
Akhlaghi, 
201246 
Iran; 53% 
Case-control 30 GDM cases  
30 non-GDM controls 
Serum iron. Matched but not stated 
on what 
characteristics. 
Glucose testing. 
Second OGTT 
(ADA criteria). 
Unadjusted serum iron levels are 
significantly lower in the GDM 
group. 
Al-Saleh, 
200447 
Kuwait; 60% 
Case-control 15 GDM cases  
15 non-GDM controls 
Serum iron. Randomly selected. Hospital record. Unadjusted serum iron levels are 
significantly lower in the GDM 
group. 
Bar, 199848 
Israel; 70% 
Case-control 28 GDM cases   
146 non-GDM controls 
 
Placental isoferritin 
(PLF). 
Not reported. Glucose testing. 
High level of 
fasting plasma 
glucose (>105 
mg/dl) or 
abnormal OGTT 
(ADA criteria). 
Unadjusted serum placental 
isoferritin levels are significantly 
lower in the second and third 
trimester of pregnancy in the 
GDM group. 
Behboudi-
Gandevani, 
201314 
Iran; 73% 
Prospective 
cohort (nested 
case-control) 
72 GDM cases  
961 non-GDM controls 
Serum iron. Not reported. Glucose testing. 
50 g GCT and 
abnormal 3-h 100g 
OGTT (Carpenter 
and Coustan 
criteria).   
Adjusted serum iron levels 
(continuous variable) are 
significantly higher in the GDM 
group (AOR: 1.01, 95% CI: 1.00, 
1.01). 
Chen, 200615 Prospective 35 GDM cases  Ferritin. Randomly selected Glucose testing. Adjusted ferritin levels (3rd tertile 
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USA; 70% cohort (nested 
case-control) 
137 non-GDM controls among non-GDM 
women in each tertile 
of serum ferritin 
concentration. 
50-g OGCT and 
OGGT. 
(Carpenter/Cousta
n conversion as 
recommended 
ADA). 
vs tertiles 1 and 2) are not 
significantly different in the 
GDM group (AOR: 1.88, 95% 
CI: 0.81, 4.36). 
Derbent, 
201334 
Turkey; 80% 
Case-control 30 GDM cases  
72 non-GDM controls 
Ferritin, serum iron, 
transferrin, hepcidin. 
Matched by 
gestational week. 
Glucose testing. 
50g GCT and 100g 
OGTT (Carpenter 
and Coustan 
modification of the 
NDDG criteria). 
Unadjusted serum ferritin, serum 
iron, and hepcidin levels are 
significantly higher in the GDM 
group.  Transferrin levels are not 
significantly different in the 
GDM group. 
Gungor, 
200731 
Turkey; 53% 
Case-control 56 GDM cases and 56 
non-GDM controls 
Ferritin, transferrin. Not reported. Glucose testing. 
50g glucose load 
screening test and 
3-h OGTT 
(Carpenter and 
Coustan OGTT 
criteria). 
Unadjusted ferritin and transferrin 
levels are not significantly 
different in GDM group. 
Kaygusuz, 
201337 
Turkey; 73% 
Case-control 30 GDM cases and 28 
non-GDM controls 
Ferritin, serum iron, 
transferrin saturation, 
TIBC 
Not reported. Glucose testing. 
50g GCT and 100g 
OGTT (Carpenter 
and Coustan 
modification of the 
NDDG criteria). 
Unadjusted serum ferritin, serum 
iron, and transferrin saturation 
levels were significantly higher 
and TIBC was significantly lower 
in the GDM group. 
Lao, 199736 
China; 73% 
Case-control 60 GDM cases  
60 non-GDM controls 
Ferritin, serum iron,  
transferrin, transferrin 
saturation. 
Matched on exact 
parity and maternal 
age (± 1y). 
Glucose testing. 
75g OGTT (WHO 
criteria). 
Unadjusted serum ferritin levels 
are significantly higher in the 
GDM group.  Serum iron, 
transferrin and transferrin 
saturation levels are not 
significantly different in the 
GDM group. 
30 
 
Lao, 200138 
China; 73% 
Case-control 97 GDM cases  
194 non-GDM controls 
Ferritin, serum iron,  
transferrin, transferrin 
saturation. 
Matched on parity, 
two controls per case. 
Glucose testing. 
Abnormal 75g 
OGTT (WHO 
criteria). 
Unadjusted serum ferritin, serum 
iron and levels are significantly 
higher and transferrin levels 
significantly lower in the GDM 
group.   
Sharifi, 
201016 
Iran; 83% 
Case-control 64 GDM cases  
64 non-GDM controls 
Ferritin. Matched on age. Glucose testing. 
50g glucose 
challenge and 3h 
OGTT (Carpenter 
Coustan criteria). 
Adjusted serum ferritin levels 
(>75th percentile) are significantly 
higher in the GDM group (AOR: 
5.1, 95% CI: 1.0-38). 
Yeniel, 
201235 
Turkey; 77% 
Case-control 29 GDM cases  
94 non-GDM controls 
Ferritin, serum iron 
transferrin, TIBC.  
Matched on age, BMI, 
gravidity, and parity 
Glucose testing. 
OGTT = 1h serum 
glucose and 50g 
glucose load 
(Carpenter and 
Coustan criteria). 
Unadjusted serum ferritin, serum 
iron, transferrin and TIBC are not 
significantly different in the 
GDM group. 
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TABLE 4 
Maternal serum iron biomarkers presented as the mean (standard deviation) in women with and without gestational diabetes mellitus (GDM) 
among studies identified in the systematic review and the in-house study. 
 
Study, country Cases 
(N) 
Controls 
(N) 
Gestational 
week at 
sampling 
Maternal serum iron biomarker Unit Biomarker level 
in cases 
Mean (SD) 
Biomarker level in 
controls 
Mean (SD) 
P-value 
Afkhami-
Ardekani, 2009 
(Iran) 
34 34 24–28  Ferritin 
Serum iron 
Transferrin saturation 
Total iron binding capacity (TIBC) 
pmol/L 
μg/l 
% 
μg/dl 
164.8 (71.3)  
1000.4 (220.9) 
26.5 (5.9) 
383.1 (30.6) 
93.4 (63.6)  
568.5 (230.3) 
12.8 (5.7) 
457.8 (58.2) 
<0.001 
<0.001 
<0.001 
<0.001 
Akhlaghi, 2012 
(Iran) 
30 30 24–28  Serum iron μg/mL 
 
73.3 (NR) 1 85.5 (NR) 1 <0.05 
Al-Saleh, 2004 
(Kuwait) 
15 15 At delivery  Serum iron μg/l 2061.6 (262.9) 2020.1 (266.0) NS1 
Bar, 1998 (Israel) 28 146 20–24  
30–34  
Serum placental isoferritin (PLF) 
Serum placental isoferritin (PLF) 
U/ml  9.4 (13.8)  
3.7 (10.0) 
21.5 (26.6)  
19 (31.4) 
<0.001 
<0.0001 
Behboudi-
Gandevani, 2013 
(Iran) 
72 961 14–20  Serum iron 
 
μg/dl 143.8 (48.7)  112.5 (69.4)  <0.0001 
Chen, 2006 (USA) 35 137 15.6 (±0.1)  Ferritin 
 
pmol/L 141 (17)  86 (9)  <0.01 
Derbent, 2013 
(Turkey) 
30 72 24-28  Ferritin 
Serum iron 
Transferrin 
Hepcidin 
pmol/L 
μg/l 
mg/L 
ng/mL 
29.7 (30.1)  
635.0 (335.0) 
384 (69) 
15.3 (9.6) 
18.9 (21.1)  
490.0 (372.0) 
361 (58) 
9.5 (3.9) 
0.008 
0.014 
NS1 
0.002 
Gungor, 2007 
(Turkey) 
56 56 28-30  Ferritin 
Transferrin 
pmol/L 
μmol/L 
38.6 (30.4)  
63.5 (18.8) 
36.5 (34.3)  
61.4 (16.6) 
NS41 
NS 
Kaygusuz, 2013 
(Turkey) 
30 28 24-28  
 
Ferritin 
Serum iron 
Transferrin saturation 
Total iron binding capacity (TIBC) 
pmol/L 
μmol/L 
% 
μmol/L 
15.5 (8.2)2  
86.5 (84.5)2 
17.9 (20.4) 
381.5 (102.5) 
7.5 (9.8)2 
58.0 (39.3)2 
12.3 (7.6) 
448.0 (95.9) 
<0.001 
0.04 
<0.01 
0.02 
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Lao, 1997 (China) 60 60 28-30  Ferritin 
Serum iron 
Transferrin 
Transferrin saturation 
pmol/L 
μg/l 
μmol/L 
% 
56.5 (33.2)  
821.0 (329.0) 
67.7 (7.7) 
22.1 (9.4) 
41.0 (42.24)  
737.2 (394.8) 
69.4 (7.7) 
19.5 (10.6) 
0.0001 
NS1 
NS 
NS 
Lao, 2001 (China) 97 194 28-30  Ferritin 
Serum iron 
Transferrin 
Transferrin saturation 
pmol/L 
μmol/L 
μmol/L 
% 
47.4 (NR) 1 
14.9 (NR) 
69.4 (NR) 
22.0 (NR) 
22.5 (NR) 1 
12.6 (NR) 
74.7 (NR) 
17.2 (NR) 
<0.0001 
0.0073 
<0.0001 
0.0004 
Sharifi, 2010 
(Iran) 
64 64 24-28  Ferritin pmol/L 112.3 (28.4)  65.0 (16.9)  0.001 
Yeniel, 2012 
(Turkey) 
29 94 12  Ferritin 
Serum iron 
Transferrin 
Total iron binding capacity (TIBC) 
pmol/L 
μg/l 
μg/dL 
μg/dL 
74.6 (126)  
790.0 (390.0) 
305.3 (60.3) 
361.3 (71.0) 
50.4 (63.7)  
956.0 (516.0) 
297.6 (78.1) 
361.5 (74.5) 
NS1 
NS 
NS 
NS 
Khambalia, 2014a 
(Australia) 
129 3, 647 9-14 Ferritin 
Transferrin receptor (TfR) 
pmol/L 
nmol/L 
43.2 (34.8)  
16.5 (5.1) 
32.9 (29.3)  
15.9 (5.7) 
0.0001 
0.11 
1Abbreviations: NS represents non-significant; NR represents not reported. 
2Values presented are median (interquartile range).
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Legend Page for Figures 
 
Figure 1 
Flowchart of selection procedure. 
 
Figure 2a 
Forest plot of all studies reporting on serum ferritin concentrations (µg/L) among women 
with and without gestational diabetes mellitus. 
 
Figure 2b 
Forest plot of select studies reporting on serum ferritin concentrations (µg/L) among women 
with and without gestational diabetes mellitus. 
 
Figure 3 
Forest plot summarising mean differences in serum iron concentrations (mcg/L) among 
women with and without gestational diabetes mellitus. 
  
34 
 
Figure 1 
Flowchart of selection procedure. 
   
35 
 
Figure 2a 
Forest plot of all studies reporting on serum ferritin concentrations (µg/L) among women 
with and without gestational diabetes mellitus. 
 
 
 
Figure 2b 
Forest plot of select studies reporting on serum ferritin concentrations (µg/L) among women 
with and without gestational diabetes mellitus. 
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Figure 3 
Forest plot summarising mean differences in serum iron concentrations (mcg/L) among 
women with and without gestational diabetes mellitus. 
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Supplementary Table 1 
Search strategies in electronic databases. 
 
Database Search number, terms (records identified) 
Ovid 
MEDLINE  
1     exp *Diabetes, Gestational/ (5246) 
2     exp *diabetes Mellitus/ (243380) 
3     ((Maternal or Gestational or pregnan*) adj3 diabet*).tw. (12728) 
4     exp *Hyperglycemia/ (14425) 
5     hyperglyc*.tw. (38285) 
6     exp *Blood Glucose/ (37240) 
7     glucose.tw. (304606) 
8     exp *Insulin Resistance/ (33280) 
9     exp *Insulin/ (76806) 
10     insulin.tw. (251694) 
11     ((elevate* or raise* or high*) adj3 glucose).tw. (22401) 
12     exp *Iron/ (42794) 
13     iron.tw. (112699) 
14     exp *Iron-Binding Proteins/ (41322) 
15     hepcidin.tw. (1774) 
16     ferritin.tw. (19025) 
17     transferrin.tw. (23287) 
18     exp *Iron Compounds/ (22902) 
19     1 or 2 or 3 (248983) 
20     4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (487709) 
21     19 and 20 (108289) 
22     12 or 13 or 14 or 15 or 16 or 17 or 18 (175931) 
23     21 and 22 (502) 
Embase 1   transferrin:ab,ti  (27,596)  
2   ferritin:ab,ti  (25,411)  
3   hepcidin:ab,ti  (3,104)  
4   iron:ab,ti  ( 148,846)  
5   'iron compounds'  (784)  
6   'iron binding proteins' (384)  
7  transferrin:ab,ti OR ferritin:ab,ti OR hepcidin:ab,ti OR iron:ab,ti OR 'iron 
compounds' OR 'iron binding proteins'(174,323) 
8  'gestational diabetes mellitus'/exp OR 'gestational diabetes mellitus'/de (19,395) 
9  diabet*:ab,ti  (548,577)                                         
10  'gestational diabetes mellitus'/exp OR 'gestational diabetes mellitus'/de AND  
     diabet*:ab,ti (15,960)   
11  transferrin:ab,ti OR ferritin:ab,ti OR hepcidin:ab,ti OR iron:ab,ti OR 'iron 
compounds' OR 'iron binding proteins' AND ('gestational diabetes mellitus'/exp 
OR 'gestational diabetes mellitus'/de) AND diabet*:ab,ti ( 129)   
CINAHL 1 (MM "Diabetes Mellitus, Gestational") (1,662) 
2 (MH "Pregnancy in Diabetes+") OR (MH "Diabetes Mellitus, Gestational") 
(3,239) 
3  TI (diabet*) (47,611) 
4 S1 OR S2 OR S3 (48,653) 
5 (MM "Preganacy+") (0) 
6 (MM "Pregnancy*") (19,571) 
7 (MM "Pregnancy Complications*") (757) 
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8 (MM "Pregnancy, High Risk") (757) 
9 TI (pregnan*) (23,681) 
10 5 OR 6 OR 7 OR 8 OR 9 (32,733) 
11 TI (hyperglyc#emia) (998) 
12 (MM "Blood Glucose") (3,711) 
13 TI (glucose) (6,444) 
14 (MM "insulin Resistance+") (5,723) 
15 (MM "Insulin+") (6,172) 
16 TI (insulin) (8,899) 
17 11 OR 12 OR 13 OR 14 OR 15 OR 16  (20,966) 
18 10 AND 17 (502) 
19 4 OR 18 (48,790) 
20 (MM "iron") (1,555) 
21 TI (iron) (2,778) 
22 TI (hepcidin) (83) 
23 TI (ferritin) (198) 
24 TI (transferrin) (117) 
25 (MM "iron compounds+") (861) 
26 20 OR 21 OR 22 OR 23 OR 24 OR 25 (3,457) 
27 19 AND 26 (83) 
 
